Protein kinase C mediates mutant N-Ras-induced developmental abnormalities in nonformal human erythroid cells

Blood

Volumn 100, Issue 12, 2002, Pages 4185-4192

  Darley, Richard L ^a   Pearn, Lorna ^a   Omidvar, Nader ^a   Sweeney, Marion ^a   Fisher, Janet ^a   Phillips, Sarah ^a   Hoy, Terry ^a   Burnett, Alan K ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; CD34 ANTIGEN; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; PROTEIN KINASE C; RAS PROTEIN; STEM CELL FACTOR;

ARTICLE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; ERYTHROBLAST; ERYTHROID CELL; ERYTHROPOIESIS; HUMAN; HUMAN CELL; MEGAKARYOCYTE; ONCOGENE N RAS; PRELEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036892733     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1358     Document Type: Article

References (61)

1. Rebollo A, Martinez-AC. Ras proteins: Recent advances and new functions, Blood. 1999;94: 2971-2980.
2. Crespo P, Leon J. Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol Life Sci. 2000;57:1613-1636.
3. Bos JL. rasoncogenes in human cancer: A review. Cancer Res. 1989;49:4682-4689.
4. Mizuki M, Fenski R, Halfter H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the ras and STAT5 pathways. Blood. 2000;96:3907-3914.
5. Goga A, McLaughlin J, Afar DEH, Saffran DC, Witte ON. Alternative signals to RAS for haematopoietic transformation by BCR-ABL oncogene. Cell. 1995;82:981-988.
6. Bollag G, Clapp DW, Shih S, et al. Loss of NF1 results in activation ot the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet, 1996;12:144-148.
7. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: A multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395-408.
8. Gallagher A, Darley RL, Padua RA. The molecular basis of myelodysplastic syndromes. Haematologica. 1997;82:191-204.
9. Kalra R, Paderanga DC, Olson K, Shannon KM. Genetic analysis is consistent with the hypothesis that NF1 limits myeloid cell growth through p21 ras. Blood. 1994;84:3435-3439.
10. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330: 597-601.
11. Darley RL, Hoy TG, Baines P, Padua RA, Burnett AK. Mutant N-RAS induces erythroid lineage dysplasia in human CD34(+) cells. J Exp Med. 1997; 185:1337-1347.
12. Chui DHK, Clarke BJ. Abnormal erythroid progenitor cells in human preleukemia. Blood. 1982;60:362-367.
13. Hoefsloot LH, vanAmelsvoort MP, Breeders LCAM, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 1997;89:1690-1700.
14. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.
15. Papayannopoulou T, Abkowitz J. Biology of erythropoiesis, erythroid differentiation, and maturation, In: Hoffman R, ed. Haematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1991:252-263.
16. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J. 1999;13:1658-1676.
17. Myklebust JH, Smeland EB, Josefsen D, Sioud M. Protein kinase C-α isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow. Blood. 2000;95:510-518.
18. Bassini A, Zauli G, Migliaccio G, et al. Lineagerestricted expression of protein kinase C isoforms in hematopoiesis. Blood. 1999;93:1178-1188.
19. Oshevski S, Bousse-Kerdiles MC, Clay D, et al. Differential expression of protein kinase C isoform transcripts in human hematopoietic progenitors undergoing differentiation. Biochem Biophys Res Commun. 1999;263:603-609.
20. Marchisio M, Bertagnolo V, Celeghini C, et al. Selective modulation of specific protein kinase C (PKC) isoforms in primary human megakaryocytic vs. erythroid cells. Anat Rec. 1999;255:7-14.
21. Rossi F, McNagny M, Smith G, Frampton J, Graf T. Lineage commitment of transformed haematopoietic progenitors is determined by the level of PKC activity. EMBO J. 1996;15:1894-1901.
22. Pierce A, Heyworth CM, Nicholls SE, et al. An activated protein kinase C α gives a differentiation signal for hematepoietic progenitor cells and mimicks macrophage colony-stimulating factor-stimulated signaling events. J Cell Biol. 1998;140: 1511-1518.
23. Racke FK, Wang D, Zaidi Z, et al. A potential role for protein kinase C-ε in regulating megakaryocytic lineage commitment. J Biol Chem. 2001; 276:522-528.
24. Lumelsky NL, Schwartz BS. Protein kinase C in erythroid and megakaryocytic differentiation: Possible role in lineage determination. Biochim Biophys Acta. 1997;1358:79-92.
25. Kovanen PE, Junttila I, Takaluoma K, et al. Regulation of Jak2 tyrosine kinase by protein kinase C during macrophage differentiation of IL-3-dependent myeloid progenitor cells. Blood. 2000;95: 1626-1632.
26. Devente J, Kiley S, Garris T, et al. Phorbol ester treatment of U937 cells with altered protein-kinase-C content and distribution induces celldeath rather than differentiation. Cell Growth Differ. 1995;6:371-382.
27. Goodnight J, Mischak H, Mushinski JF. Selective involvement of protein-kinase-C isozymes in difterentiation and neoplastic transformation. Adv Cancer Res. 1994;64:159-209.
28. Grignani F, Kinsella T, Mencarelli A, et al. Highefficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein. Cancer Res. 1998;58:14-19.
29. Toullec D, Pianetti P, Coste H, et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991;266:15771-15781.
30. Gallagher AP, Burnett AK, Bowen DT, Darley RL. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process. Cancer Res. 1998; 58:2029-2035.
31. Civin CI. Human monomyeloid cell membrane antigens. Exp Hematol. 1990;18:461-467.
32. Freyssinier JM, LecoqLafon C, Amsellem S, et al. Purification, amplification and characterization of a population of human erythroid progenitors. Br J Haematol. 1999;106:912-922.
33. Debili N, Robin C, Schiavon V, et al. Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. Blood. 2001;97:2023-2030.
34. Basch RS, Zhang XM, Dolzhanskiy A, Karpatkin S. Expression of CD41 and c-mpl does not indicate commitment to the megakaryocyte lineage during haemopoietic development. Br J Haematol. 1999;105:1044-1054.
35. Lepage A, Leboeuf M, Cazenave JP, et al. The a(IIb)β(3) integrin and GPlb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. Blood. 2000;96:4169-4177.
36. Buhring HJ, Seiffert M, Bock TA, et al. Expression of novel surface antigens on early hematopoietic cells. Ann N Y Acad Sci. 1999;872:25-39.
37. Papayannopoulou T, Brice M. Integrin expression profiles during erythroid differentiation. Blood. 1992;79:1686-1694.
38. - progenitor cells. Blood. 1991;77:1218-1227.
39. Lansdorp PM, Sutherland HJ, Eaves CJ. Selective expression of CD45 isoforms on functional subpopulations of CD34+ hemopoietic cells from human bone marrow. J Exp Med. 1990;172:363-366.
40. Chida D, Miura O, Yoshimura A, Miyajima A. Role of cytokine signaling molecules in erythroid differentiation of mouse fetal liver hematopoietic cells: Functional analysis of signaling molecules by retrovirus-mediated expression. Blood. 1999;93: 1567-1578.
41. Mackenzie ML, Doinikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood. 1999;93:2043-2056.
42. Matsumura I, Kawasaki A, Tanaka H, et al. Biologic significance of GATA-1 activities in Ras-mediated megakaryocytic differentiation of hematopoietic cell lines. Blood. 2000;96:2440-2450.
43. Goldfarb AN, Wong D, Racke FK. Induction of megakaryocytic differentiation in primary human erythroblasts: A physiological basis for leukemic lineage plasticity. Am J Pathol. 2001;158:1191-1198.
44. Parekh DB, Ziegler W, Parker PJ. Multiple pathways control protein kinase C phosphorylation. EMBO J. 2000;19:496-503.
45. Diaz-Laviada I, Larrodera P, Diaz-Meco MT, et al. Evidence for a role of phosphatidylcholine-hydrolysing phospholipase C in the regulation of protein kinase C by ras and src oncogenes. EMBO J. 1990;9:3907-3912.
46. Brada SJL, deWolf JTW, Hendriks DW, Smit JW, Vellenga E. CD34(+)/CD36(-) cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia. 1998;12:882-886.
47. Backx B, Broeders L, Hoefsloot LH, Wognum B, Lowenberg B. Erythropoiesis in myelodysplastic syndrome: Expression of receptors for erythropoietin and kit ligand. Leukemia. 1996;10:466-472.
48. Bouscary D, Preudhomme C, Ribrag V, et al. Prognostic value of c-mpl expression in myelodysplastic syndromes. Leukemia. 1995;9:783-788.
49. Pellegrini W, Facchetti F, Marocolo D, et al. Expression of CD34 by megakaryocytes in myelodysplastic syndromes. Haematologica. 2000;85: 1117-1118.
50. Gougopoulou DM, Kiaris H, Ergazaki M, et al. Mutations and expression of the ras family genes in leukemias. Stem Cells. 1996;14:725-729.
51. Gallagher AP, Padua RA, Alsabah A, Burnett AK, Darley RL. Overexpression of p21 RAS but not p120GAP is a common feature of myelodysplasia. Leukemia. 1995;9:1833-1840.
52. Muszynski KW, Thompson D, Hanson C, et al. Growth factor-independent proliferation of erythroid cells infected with Friend spleen focusforming virus is protein kinase C dependent but does not require Ras-GTP. J Virol. 2000;74:8444-8451.
53. Le Naour F, Francastel C, Prenant M, et al. Upregulation of CD9 expression during TPA treatment of K562 cells. Leukemia. 1997;11:1290-1297.
54. Fackler MJ, Civin CI, May WS. Up-regulation of surface CD34 is associated with protein kinase C-mediated hyperphosphorylation of CD34. J Biol Chem. 1992;267:17540-17546.
55. Mufson RA. The role of serine/threoaine phosphorylation in hematopoietic cytokine receptor signal transduction. FASEB J. 1997;11:37-44.
56. Cullen PJ. Ras effectors: Buying shares in Ras plc. Curr Biol. 2001;11:R342-R344.
57. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood. 1996; 88:1284-1296.
58. von Lindern M, Parren-van Amelsvoort M, van Dijk T, et al. Protein kinase C α controls erythropoietin receptor signaling. J Biol Chem. 2000; 275:34719-34727.
59. Jamieson L, Carpenter L, Biden TJ, Fields AP, Protein kinase C-activity is necessary for Bcr-Abl-mediated resistance to drug-induced apoptosis. J Biol Chem. 1999;274:3927-3930.
60. Evans CA, Lord JM, Owen-Lynch PJ, et al. Suppression of apoptosis by v-ABL protein tyrosine kinase is associated with nuclear translocation and activation of protein kinase C in an interleukin-3-dependent haemopoietic cell line. J Cell Sci. 1995;108(pt 7):2591-2598.
61. Chalandon Y, Jiang X, Hazlewood G, et al. Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming. Blood. 2002;99:3197-3204.